US Patent

US9833419 — Transdermal estrogen device and delivery

Formulation · Assigned to Noven Pharmaceuticals Inc · Expires 2028-07-10 · 2y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a transdermal drug delivery system for administering estrogen, comprising a polymer matrix and estrogen.

USPTO Abstract

Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Drugs covered by this patent

Estrace (ESTRADIOL) · Pfizer

Patent Metadata

Patent number: US9833419
Jurisdiction: US
Classification: Formulation
Expires: 2028-07-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Noven Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.